| Decentralized Trials: Reshaping the Rare Disease Landscape | Editors | 10/29/20 | Boston |
| Sanofi, Pfizer & Bristol Drugs Among the 12 Approvals to Look Out for in Q4 | Alex Shimmings | 10/15/20 | National |
| Vertex Stops Test of Rare Disease Drug, Dimming Pipeline Prospects | Frank Vinluan | 10/15/20 | Boston |
| Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin | Frank Vinluan | 10/14/20 | Boston |
| Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies | Frank Vinluan | 10/14/20 | Boston |
| Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma | Frank Vinluan | 10/13/20 | San Diego |
| SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D | Frank Vinluan | 10/12/20 | Boston |
| “Opioid Stacking” Concerns Lead FDA to Reject Avenue Therapeutics Drug | Frank Vinluan | 10/12/20 | New York |
| FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats | Frank Vinluan | 10/09/20 | Europe |
| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility | Sue Sutter | 10/08/20 | Boston |
| In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug | Frank Vinluan | 10/08/20 | National |
| BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting | Editors | 10/08/20 | Boston |
| Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter | Frank Vinluan | 10/06/20 | San Francisco |
| Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs | Frank Vinluan | 10/06/20 | Boston |
| Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B | Frank Vinluan | 10/05/20 | New York |
| Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity | Mandy Jackson | 10/02/20 | National |
| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume | Frank Vinluan | 10/01/20 | Boston |
| Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries | Frank Vinluan | 10/01/20 | Europe |
| Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China | Frank Vinluan | 09/30/20 | New York |
| With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug | Frank Vinluan | 09/30/20 | New York |
| Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins | Frank Vinluan | 09/29/20 | Europe |
| Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs | Frank Vinluan | 09/28/20 | Boston |
| Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward | Frank Vinluan | 09/25/20 | Europe |
| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Combined Therapeutics Inc Wins $250,000 MilliporeSigma Advance Biotech Grant | Editors | 09/25/20 | National |
| Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs | Frank Vinluan | 09/24/20 | Boston |
| And the 2020 National Xconomy Awards Winners Are… | Editors | 09/24/20 | National |
| Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders | Frank Vinluan | 09/23/20 | San Diego |
